Montefiore registers Phase 1 trial pairing Talquetamab with belantamab mafodotin in myeloma

The only update for GlaxoSmithKline this week concerns a newly listed early-phase myeloma study where GSK serves as a collaborator to lead sponsor Montefiore Medical Center.

• A Phase 1 dose escalation trial called "TaBleMM" (NCT07720843) was first posted on 2026-07-22 and is not yet recruiting, with an estimated start of 2026-09-01. The study is described as an open-label dose escalation study evaluating safety and clinical efficacy of Talquetamab combined with Belantamab mafodotin for a time-limited interval, followed by maintenance with Belantamab mafodotin and Pomalidomide.¹
• Eligible patients are those with relapsed or refractory multiple myeloma who have already received at least one prior line of therapy and have been treated with IMiDs, proteasome inhibitors, and anti-CD38 therapies either in combination or as single agent¹.
• Dosing follows a step-up schedule: Talquetamab is given with step-up dosing on day 1, 3, 5, with or without day 7, followed two weeks later by enrollment on Cycle 1 Day 1 with Belantamab; Talquetamab then continues every two weeks while Belantamab is dosed every 8 weeks on Day 1 of odd-numbered cycles or until ocular toxicities resolve to grade 1 or better.¹
• The trial runs in two parts, moving from dose escalation to an expansion phase once the maximum tolerated dose of the combination is determined, with expansion cohorts enrolling participants across 2 dose levels aimed at identifying the optimal biological dose and confirming safety and secondary efficacy endpoints¹.
• Planned enrollment is 50 participants (estimated)¹, with an estimated primary completion date of 2030-03¹.